LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually.The post [Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m](https://www.pehub.com/nordic-capital-backed-leo-pharma-to-acquire-dersimelagon-rights-from-bain-owned-tanabe-for-435m/) appeared first on [PE Hub](https://www.pehub.com).